Home/Pipeline/Semaglutide (Oral Generic)

Semaglutide (Oral Generic)

Type 2 Diabetes, Obesity

Pre-launchPlanned for FY27N/A

Key Facts

Indication

Type 2 Diabetes, Obesity

Phase

Pre-launch

Status

Planned for FY27

Company

dr-reddys-laboratories

About dr-reddys-laboratories

Founded in 1984, Dr. Reddy's has evolved from an API manufacturer into a fully integrated global pharmaceutical enterprise with a mission to provide affordable and innovative medicines. Its strategy is built on a four-pillar business model—Generics, API & Services, Innovative Medicines, and Consumer Health—leveraging deep scientific capabilities in complex generics, biosimilars, and novel drug discovery. Recent milestones, including the launch of India's first generic semaglutide and key biosimilar approvals in major markets, underscore its growth trajectory and commitment to addressing unmet patient needs globally.

View full company profile

Therapeutic Areas

Oncology Diabetes & Metabolic Disorders Gastroenterology Infectious Diseases Immunology Central Nervous System Cardiovascular

Other Type 2 Diabetes, Obesity Drugs

Drug	Company	Phase	Status
Generic Semaglutide (Oral)	Dr. Reddy's Laboratories	Development	Targeted launch FY27
Semaglutide Injection	lupin	Market	Licensed for India
GLP-1 Agonist Program	Biolingus	Pre-clinical	Active
GLP-1 Receptor Agonist (Gan & Lee)	Lupin Limited	Clinical Development	Licensed (Active)